CoChat

Management and Outcomes of Cardiac Sarcoidosis: A 20-Year Experience in Two Tertiary Care Centres

Open access
Fussner, Lynn A., Karlstedt, Erin, Hodge, David O., Fine, Nowell M., Kalra, Sanjay, Carmona, Eva M., Utz, James P., Isaac, Debra L., Cooper, Leslie T. · 2018 · European Journal of Heart Failure
Cited by 99

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

Aims: Cardiac sarcoidosis (CS) often presents with ventricular arrhythmias, heart block, and cardiomyopathy. The prognosis of CS with contemporary management is uncertain. We estimated the impact of baseline and treatment variables on left ventricular ejection fraction (LVEF), ventricular assist device placement, heart transplant, and death. Methods and results: We identified patients with CS seen from 1994–2014 at two large academic medical centres. All met the 2014 Heart Rhythm Society expert consensus criteria for diagnosis. From the 574 patients identified, 91 met inclusion criteria. Twenty-two (24.2%) were diagnosed by endomyocardial biopsy. Cardiomyopathy was the primary presentation in 47 patients (51.6%). Within 90 days of diagnosis, 41 patients (45.0%) received prednisone alone, 29 (31.9%) received alternative immunosuppression with or without prednisone, and 21 (23.1%) received no immunosuppression. During follow-up, 31 of 47 cardiomyopathy patients experienced improvement in LVEF, while 23 experienced decline in LVEF or clinical exacerbation, and 15 of 22 patients presenting with ventricular arrhythmia had recurrence. These results did not differ by treatment group. During a median follow-up of 44 months for our cohort, 14 patients reached the composite endpoint of ventricular assist device placement, heart transplant, or death. Survival without the composite outcome did not differ by treatment group, but was worse among patients presenting with cardiomyopathy (log-rank = 0.005). Conclusion: In a large series of CS subjects, rates of ventricular arrhythmia and heart failure events remain high with no treatment regimen clearly associated with better outcome. Patients with cardiomyopathy at diagnosis were more likely to reach the composite endpoint.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/ejhf.1319

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 99

Metadata

Authors
Fussner, L. A., Karlstedt, E., Hodge, D. O., Fine, N. M., Kalra, S., Carmona, E. M., Utz, J. P., Isaac, D. L., & Cooper, L. T.
Venue
European Journal of Heart Failure
Published
2018-10-31
Volume
20
Issue
12
Pages
1713-1720
ISSN
  • 1388-9842 (ISSN-L)
  • 1879-0844
OpenAlex
W2899339705
Cited by
99
References
2
FWCI
5.05
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Management and Outcomes of Cardiac Sarcoidosis: A 20-Year Experience in Two Tertiary Care Centres. https://app.cochat.ai/papers/10.1002/ejhf.1319
The paper
Fussner, L. A., Karlstedt, E., Hodge, D. O., Fine, N. M., Kalra, S., Carmona, E. M., Utz, J. P., Isaac, D. L., & Cooper, L. T. (2018). Management and Outcomes of Cardiac Sarcoidosis: A 20-Year Experience in Two Tertiary Care Centres. European Journal of Heart Failure. https://doi.org/10.1002/ejhf.1319

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.